CD274 and diffuse large B-cell lymphoma: Infusion‐related reactions were the most common, with an incidence of 38.9%, 75.0%, 52.9%, and 72.7% in cHL anti‐PD‐1/PD‐L1 naïve, cHL anti‐PD‐1/PD‐L1 progressor, DLBCL, and PTCL cohorts, respectively.